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ABSTRACT The hypoxia-inducible factors (HIFs; iso-
forms HIF-1, HIF-2, HIF-3) mediate many responses
to hypoxia. Their regulation is principally by oxygen-
dependent degradation, which is initiated by hydroxyla-
tion of specific proline residues followed by binding of
von Hippel-Lindau (VHL) protein. Chuvash polycythe-
mia is a disorder with elevated HIF. It arises through
germline homozygosity for hypomorphic VHL alleles
and has a phenotype of hematological, cardiopulmo-
nary, and metabolic abnormalities. This study explores
the phenotype of two other HIF pathway diseases:
classic VHL disease and HIF-2 gain-of-function muta-
tion. No cardiopulmonary abnormalities were detected
in classic VHL disease. HIF-2 gain-of-function muta-
tions were associated with pulmonary hypertension,
increased cardiac output, increased heart rate, and
increased pulmonary ventilation relative to metabolism.
Comparison of the HIF-2 gain-of-function responses
with data from studies of Chuvash polycythemia sug-
gested that other aspects of the Chuvash phenotype
were diminished or absent. In classic VHL disease,
patients are germline heterozygous for mutations in
VHL, and the present results suggest that a single
wild-type allele for VHL is sufficient to maintain normal
cardiopulmonary function. The HIF-2 gain-of-func-
tion phenotype may be more limited than the Chuvash
phenotype either because HIF-1 is not elevated in the
former condition, or because other HIF-independent
functions of VHL are perturbed in Chuvash polycythe-
mia.—Formenti, F., Beer, P. A., Croft, Q. P. P., Dor-
rington, K. L., Gale, D. P., Lappin, T. R. J., Lucas, G. S.,
Maher, E. R., Maxwell, P. H., McMullin, M. F.,
O’Connor, D. F., Percy, M. J., Pugh, C. W., Ratcliffe,
P. J., Smith, T. G., Talbot, N. P., Robbins, P. A.
Cardiopulmonary function in two human disorders of
the hypoxia-inducible factor (HIF) pathway: von Hip-
pel-Lindau disease and HIF-2 gain-of-function muta-
tion. FASEB J. 25, 2001–2011 (2011). www.fasebj.org
Key Words: pulmonary hypertension  ventilation  metabo-
lism  polycythemia
The hypoxia-inducible factor (HIF) family of tran-
scription factors orchestrates a coordinated response to
variations in oxygen availability by directly or indirectly
altering the expression of hundreds of genes (1–4).
These factors are composed of two subunits: the oxy-
gen-regulated HIF (isoforms are HIF-1, HIF-2, or
HIF-3) and the constitutively expressed HIF (5). In
the presence of oxygen at physiological levels, HIF
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undergoes rapid proteasomal degradation (6), trig-
gered by prolyl hydroxylation (7–11), and subsequent
binding to the von Hippel-Lindau (VHL) tumor sup-
pressor protein (12, 13). When oxygen falls below
physiological levels, the rate of hydroxylation slows, and
HIF accumulates within the cell.
Chuvash polycythemia (CP) is a rare disorder caused by
germline homozygosity for a hypomorphic allele of VHL,
which increases the levels of HIF within cells (14, 15). It is
associated with a specific phenotype of excessive erythro-
cytosis, increased pulmonary ventilation and arterial hy-
pocapnia, pulmonary hypertension, excessive pulmonary
vascular and ventilatory responses to hypoxia, early and
marked accumulation of lactate during exercise, limited
exercise capacity, and shortened life expectancy (16–19).
This study explores the phenotype of two other genetic
disorders of the HIF-signaling pathway.
Classic VHL disease arises through a heterozygous
mutation in VHL that has a severe effect on function of
the associated protein (20). In this hereditary cancer
syndrome, tumors form following a second (somatic)
mutation, so that the function of both alleles of VHL in
these cells has been disrupted (21–23). In this disease, a
systemic phenotype would not be predicted without some
degree of haploinsufficiency in relation to VHL. As there
is now some evidence for this (ref. 24; see Discussion), our
first aim (VHL study) was to determine whether any aspects
of the CP phenotype are detectable in classic VHL disease.
Germline, heterozygous gain-of-function mutations in
HIF-2 form a further type of disorder of the HIF pathway
(25–27). These mutations in HIF-2 are associated with
excessive erythrocytosis, but it is unknown whether other
aspects of the CP phenotype are reproduced in these
patients. As there is no evidence that these gain-of-
function mutations in HIF-2 affect HIF-1 protein levels,
the associated phenotype could be smaller than in CP.
Our second aim (HIF2 study) was to determine what
other aspects of the CP phenotype are also present in




Six patients with classic VHL disease (VHL patients) and 6
healthy control participants took part in the study. The
patients were free from any associated neoplasia at the time of
the study and had no other medical disorders. VHL patients
were recruited through their respective physicians. Control
participants were recruited through advertisement and were
chosen to match VHL patients for sex, age, height, weight,
and body mass index.
HIF2 study
Three patients with gain-of-function mutations in HIF-2
(HIF2 patients) and 6 healthy control participants took part
in the study. The patients had not been venesected within
several weeks of the experiment and had no other medical
disorders. They were identified from previous studies (25, 28)
and recruited through their respective physicians. The num-
ber of patients recruited was limited by the rarity of the
condition. Control participants were recruited through adver-
tisement and were chosen to match HIF2 patients for sex,
age, height, weight, and body mass index.
In both studies, all participants were informed about the
aims, procedure, and details of the study and signed a consent
form before taking part in the experiments. The studies
conformed to the Declaration of Helsinki and had been
approved by the Oxfordshire Research Ethics Committee.
Experimental protocol
Experiments were performed during the course of a single
day. Participants were asked to avoid vigorous exercise and
alcohol and caffeine consumption for 48 h prior to the
experiments; they were also asked to eat a light breakfast on
the morning of the experimental day. Room temperature was
kept at 21°C throughout. Air-breathing end-tidal partial pres-
sures of oxygen (PETo2) and carbon dioxide (PETco2) were
measured before venous and arterial blood samples were
taken. Participants were then asked to undertake four 20-min
hypoxia response protocols, separated by three 20-min inter-
vals. Each protocol started with 5 min of isocapnic euoxia
(PETo2 100 mmHg), followed by 10 min of isocapnic hypoxia
and ended with a final 5 min of isocapnic euoxia. The first
two protocols examined the responses to mild hypoxia (PETo2
70 mmHg), similar to those experienced on a commercial
flight. The last two protocols examined the responses to mod-
erate hypoxia (PETo2 50 mmHg), similar to those associated
with acute exposure to an altitude of 3500 m. PETco2 was
maintained close to each participant’s baseline level throughout
each protocol. For the HIF2 study only, participants undertook
an incremental exercise test to exhaustion after the hypoxia
response protocols had been completed. For one HIF2 patient,
the experiments were repeated on a second occasion after the
patient had undergone a program of venesection to reduce his
hematocrit to within the normal range.
Experimental technique
Respiratory measurements and control of end-tidal gases
During the hypoxia response protocols, participants had
their nostrils occluded and breathed through a mouth-
piece connected to a turbine used to measure ventilation
(29). Respired gases were sampled through a catheter and
analyzed continuously by mass spectrometry. The control of
gases was managed through the dynamic end-tidal forcing
technique: end-tidal measured values were used as input for a
computer that controlled a fast gas-mixing system, which, in
turn, allowed a rapid and accurate manipulation of PETo2 and
PETco2 in the subsequent breaths (30). Breath-by-breath
PETo2, PETco2, and ventilation values were recorded on a
computer in real time. Throughout each protocol, partici-
pants were asked to recline in the left lateral position on a
suitably modified couch.
Echocardiographic measurements
Pulmonary arterial systolic pressure and cardiac output were
estimated through a continuous recording of Doppler echo-
cardiography (Vivid-i; GE Healthcare, Little Chalfont, UK)
with a 2-dimensional S3 probe (1.5–3.6 MHz). In the first and
third protocols, pulmonary arterial systolic pressure was esti-
mated by measurement of the maximum gradient of blood
pressure across the tricuspid valve. This technique has been
2002 Vol. 25 June 2011 FORMENTI ET AL.The FASEB Journal  www.fasebj.org
extensively validated (31–36). Right atrial pressure is not
affected by hypoxia (37), so variations in the maximum
gradient of blood pressure across the tricuspid valve mirror
variations in pulmonary arterial systolic pressure. In the
second and fourth protocols, cardiac output was estimated by
measuring the velocity of blood flow through the aortic valve
(38–40). An automatic monitor (Omron M5-I; Omron
Healthcare Co., Kyoto, Japan) was used to measure blood
pressure and heart rate every minute.
Incremental exercise test to exhaustion for HIF2 study
In the HIF2 study, exercise capacity was measured through an
incremental exercise test to exhaustion on a modified, elec-
trically braked cycle ergometer (Mijnhardt KEM3; Cardioki-
netics, Salford, UK). Participants were given 30 s to achieve
the required pedaling frequency (65 rpm) before the
workload was increased by 20 W/min until exhaustion. Ex-
haustion was defined as the point at which the participants
could no longer maintain the required pedaling frequency.
Venous blood was sampled at the end of each work load (i.e.,
every minute) in order to measure venous blood lactate
concentration. During the course of the protocol, partici-
pants breathed through a mouthpiece, with their nostrils
occluded, and respiratory measurements were made as de-
scribed for the hypoxia response protocols.
Data analysis
Measurements of PETo2, PETco2, ventilation, the maximum
gradient of blood pressure across the tricuspid valve, and
cardiac output were averaged over 1-min periods prior to
further analysis. Differences between patients and control
participants were assessed statistically using ANOVA (SPSS
12.0; SPSS, Chicago, IL, USA). Statistical significance was
assumed at values of P  0.05. Variables are presented as
means  sd, unless otherwise stated.
RESULTS
VHL study
Details of the specific mutation for each VHL patient,
together with the physical characteristics of patients and
control participants, are given in Supplemental Table S1.
The physical characteristics of patients and control partic-
ipants were well matched. VHL patients did not differ
significantly from control participants in arterial Pco2,
arterial pH, hemoglobin, hematocrit, mean corpuscular
volume, serum iron, ferritin, and transferrin (Supplemen-
tal Table S2). In 3 VHL patients and in 1 control partic-
ipant, the arterial Po2 was lower than is predicted for their
age, but average arterial Po2 did not differ significantly
between VHL patients and control participants.
Pulmonary measurements
VHL patients did not differ significantly from control
participants in either baseline ventilation or in the incre-
ment in ventilation with mild or moderate hypoxia. The
responses are illustrated in Supplemental Fig. S1.
An element of tricuspid regurgitation was detectable
echocardiographically in 5 of the 6 VHL patients, but in
only 2 of the control participants. VHL patients did not
differ significantly from control participants in either
baseline pulmonary arterial systolic pressure or in the
increments in that pressure with mild or moderate
hypoxia. The responses are illustrated in Supplemental
Fig. S1. These responses were also similar to those of
the control participants for the HIF2 study.
Systemic vascular measurements
The systemic vascular responses to hypoxia are illus-
trated in Supplemental Fig. S2. VHL patients did not
differ significantly from control participants in either
baseline values for heart rate, blood pressure, and
cardiac output or in the increments in these variables
with mild or moderate hypoxia.
Summary of VHL study
Figure 1 illustrates the deviation of each participant’s
baseline value (or incremental response) from the mean
value for the control group, expressed in units of sd of the
control group. There was considerable overlap between
VHL patients and control participants for all variables.
HIF2 study
Details of the specific mutations for each HIF2 patient,
together with the physical characteristics of patients
and control participants, are given in Supplemental
Table S3. The physical characteristics of the patients
and control participants were well matched. The results
obtained from the analysis of the venous and arterial
blood samples are given in Table 1. Compared with the
control participants, HIF2 patients had lower arterial
Pco2 (10.65.3 mmHg, P0.01), higher hemoglobin
concentration (2.40.9 g/dl, P0.03), higher hemato-
crit (0.080.03 L/L, P0.03), and higher value for
transferrin (0.80.3 g/L, P0.003). HIF2 patients did
not differ significantly from control participants in arterial
pH, mean corpuscular volume, serum iron, and ferritin.
Pulmonary measurements
HIF2 patients did not differ significantly from control
participants in either baseline ventilation or increment
in ventilation with mild or moderate hypoxia. The
responses are illustrated in Fig. 2.
Echocardiographic measurements of pulmonary arte-
rial systolic pressure were possible in 2 HIF2 patients and
4 control participants. Compared with the control partic-
ipants, the HIF2 patients had significantly higher pulmo-
nary arterial systolic pressures at baseline (352 vs. 241
mmHg, HIF2 patients vs. control participants, P0.003),
and a significantly greater increase in pulmonary arterial
systolic pressure in response to moderate hypoxia (111
vs. 51 mmHg, P0.004). HIF2 patients did not differ
significantly from control participants in the increase in
pulmonary arterial systolic pressure with mild hypoxia.
The responses are illustrated in Fig. 2.
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Systemic vascular measurements
Figure 3 illustrates the systemic vascular responses to
hypoxia. At baseline, compared with the control partic-
ipants, the HIF2 patients had significantly higher heart
rate (712 vs. 568 beats/min, P0.02) and signifi-
cantly greater cardiac output (5.51.0 vs. 4.10.5
L/min, P0.02), while they did not differ significantly
in blood pressure. HIF2 patients did not differ signifi-
cantly from control participants in the increments in
Figure 1. Cardiopulmonary variables in both the VHL and HIF2 studies: baseline measurements (A, B) and incremental responses
with mild hypoxia (C, D) and moderate hypoxia (E, F). Results are shown in terms of number of (control group) sd by which each
participant’s baseline and response differed from the mean baseline and mean response, respectively, of the control participants. Red
symbols show average results for patient groups. A, C, E) VHL patients were not significantly different from the control participants
for any variable. B, D, F) Under baseline conditions, HIF2 patients had significantly higher pulmonary arterial pressure, heart rate,
and cardiac output than control participants. Compared with control participants, HIF2 patients also had a significantly greater rise
in pulmonary arterial pressure with moderate hypoxia. VE, ventilation; PASP, pulmonary arterial systolic pressure; HR, heart rate; SBP,
systolic blood pressure; DBP, diastolic blood pressure; CO, cardiac output; , increment.
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heart rate, blood pressure, and cardiac output with
mild or moderate hypoxia.
Summary of cardiopulmonary responses for HIF2 study
Figure 1 presents a summary of the variations in both
baseline values and in the incremental responses to
hypoxia for the various cardiopulmonary measure-
ments. For baseline pulmonary arterial systolic pres-
sures and for the increments in pulmonary arterial
systolic pressure with moderate hypoxia, no overlap was
observed in responses between the control participants
and the HIF2 patients. For other variables, there was
some overlap between the two groups, although the
cardiac output of 2 of the 3 HIF2 patients was 	3 SD
from the mean of the control participants.
Incremental exercise test to exhaustion
Figure 4 illustrates the responses obtained during the
incremental exercise test to exhaustion. The rise in
venous lactate with work rate appeared to be similar
between HIF2 patients and control participants. Two of
the 3 HIF2 patients appeared somewhat limited in their
maximum exercise capacity, but the third patient exer-
cised very comparably with the control participants.
Overall, there were no significant differences between
HIF2 patients and control participants for the maxi-
mum work rate achieved and the associated lactate level
attained (2.00.9 vs. 2.90.9 W/kg, NS; and 4.32.2
vs. 5.42.7 mM, NS; respectively). The hyperventila-
tion and associated hypocapnia at rest persisted
throughout the period of incremental exercise to ex-
haustion.
Effects of venesection on one of the HIF2 patients
One of the HIF2 patients (patient 2) was studied both
before and after venesection, which reduced the hemo-
globin and hematocrit to values within the normally
accepted range, serum iron to 7.8 
M, ferritin to 8.9

g/L, and increased transferrin concentration to 4.24
g/L (Supplemental Table S4).
Venesection in this patient had no clear effect on
ventilation and pulmonary arterial systolic pressure
(Supplemental Fig. S3); ventilation appeared normal,
while pulmonary arterial systolic pressure remained
above normal. Venesection had no clear effect on heart
rate, blood pressure, and cardiac output (Supplemen-
tal Fig. S4) at baseline and with hypoxia. Also, venesec-
tion had no clear effect on the accumulation of lactate
in venous blood, ventilation, and end-tidal pressure of
carbon dioxide (Supplemental Fig. S5), and on the
maximum work rate and maximum venous blood lac-
tate concentration achieved during the incremental
exercise test to exhaustion; all these parameters re-
mained within the normally accepted range (Supple-
mental Table S4).
DISCUSSION
In patients with classic VHL disease, the tumors that
occur always have a somatic mutation of the wild-type
allele for VHL, and, for this reason, it has generally
been assumed that a single normal allele for VHL is
sufficient to maintain normal cellular function. Re-
cently, however, it has been shown that freshly isolated
neutrophils from VHL patients displayed delayed apo-
ptosis and enhanced bacterial phagocytosis, consistent
with a pseudohypoxic phenotype (24). Haploinsuffi-
ciency resulting in HIF activation was further supported
by the presence of elevated levels of PHD3 transcript in
these cells, which is a known HIF target gene (41, 42).
From these observations, the researchers concluded
that, in humans, “heterozygous VHL defects are suffi-
cient to perturb normal responses” (24), at least in
some cells.
Despite this conclusion, erythrocytosis is not a fea-
ture of VHL disease, except in the context of cerebellar
or renal tumors. In these cases, erythrocytosis is due to
unregulated erythropoietin production from the tumor
tissue, where both copies of VHL are mutated. Removal
of the tumor tissue corrects the erythrocytosis, confirm-
ing that the underlying regulation is normal in the
context of a single wild-type allele for VHL (43). In a
relatively small number of VHL patients, the present
study did not detect any of the major cardiopulmonary
abnormalities present in the CP phenotype. Thus, a
single functional allele for VHL appears to be sufficient
TABLE 1. Arterial and venous blood analyses
Analysis Normal range HIF2, n  3 Control, n  6 P value
Arterial Po2 (mmHg) 83–105 105.0  13.0 99.8  9.5 0.52
Arterial Pco2 (mmHg) 35–45 32.1  6.5 42.7  3.7 0.01
Arterial pH 7.35–7.45 7.43  0.04 7.38  0.04 0.10
Hemoglobin (g/dl) 13–17 18.5  1.8 16.1  1.0 0.03
Hematocrit (L/L) 0.40–0.50 0.57  0.05 0.49  0.03 0.03
Mean corpuscular volume (fl) 83–105 84.6  21.2 89.6  2.8 0.56
Serum iron (
M) 14–31 17.0  10.3 18.7  4.6 0.75
Ferritin (
g/L) 20–300 75.8  66.3 162.9  93.2 0.27
Transferrin (g/L) 1.8–3.6 3.5  0.2 2.7  0.2 0.003
Values are means  sd. P values compare the HIF2 patient group with the respective matched control participant group.
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Figure 2. End-tidal gas control, ventilation, and pulmonary arterial systolic pressure during mild and moderate hypoxia. A, B) PETo2
and PETco2 in mild hypoxia (A) and moderate hypoxia (B). PETo2 was well matched between groups. PETco2 was lower for the HIF2
patients, reflecting their lower baseline air-breathing PETco2. C, D) Ventilation, given at body temperature and pressure, saturated
with water vapor, in mild (C) and moderate hypoxia (D). Baseline ventilation and the increase in ventilation provoked by hypoxia were
not significantly different between the two groups. E, F) Pulmonary arterial systolic pressure. Compared with control participants,
HIF2 patients had elevated pulmonary arterial systolic pressures at baseline (242 vs. 351 mmHg, P0.003), and increased
sensitivity to moderate (F) but not mild (E) hypoxia (5.51.3 vs. 11.50.7 mmHg, P0.004). Values are expressed as means  sd.
Horizontal black bars indicate 10-min periods of mild (A, C, E) and moderate (B, D, F) exposures to hypoxia.
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to ensure either normality, or at least near normality,
for these components of the CP phenotype.
In common with CP, gain-of-function mutations in
HIF-2 were first identified through excessive eryth-
rocytosis (14, 28). This similarity between the two
conditions suggests that, in CP, elevation of HIF-2
alone may be sufficient to generate the erythrocyto-
sis. Consistent with this, erythrocytosis in a mouse
model of CP can be reversed by loss of the HIF-2
allele in VHLR/RHIF2-/ mice (where R indicates
Figure 3. Systemic vascular responses in HIF2 patients and control participants to mild and moderate hypoxia. A, B) Heart rate
in mild hypoxia (A) and moderate hypoxia (B). At baseline, heart rate was significantly higher in the HIF2 patients than in the
control participants (P0.02). C, D) Systolic (top) and diastolic (bottom) blood pressure in mild (C) and moderate hypoxia (D).
Blood pressure did not differ significantly between the two groups. E, F) Cardiac output, assessed noninvasively using Doppler
echocardiography, in mild (E) and moderate hypoxia (F). At baseline, cardiac output was significantly greater in the HIF2
patients than in the control participants (P0.02). Increments in heart rate, blood pressure, and cardiac output with hypoxia
did not differ significantly between the two groups. Values are expressed as means  sd. Horizontal black bars indicate 10-min
periods of mild (A, C, E) and moderate (B, D, F) exposures to hypoxia.
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the Chuvash allele), but not by loss of the HIF-1
allele in VHLR/RHIF1-/ mice (46).
Components of the CP phenotype (18) identified in
the HIF2 patients in this study include the pulmonary
hypertension present under air breathing conditions
and the elevation of pulmonary ventilation in relation
to metabolism, as indicated by arterial and end-tidal
hypocapnia. Indeed, clinically severe pulmonary hyper-
tension has already been noted in two HIF2 patients
from one family (25). Again, these findings suggest that
elevation of HIF-2 alone in CP may be sufficient to
generate these components of the phenotype. Consis-
tent with this notion, pulmonary hypertension, which is also
present in the mouse model of CP, was reduced in severity in
VHLR/RHIF2-/ mice, but not in VHLR/RHIF1-/
mice (46). Overall, these findings suggest that HIF-1
may have little physiological role in the regulation of
basal ventilation, pulmonary blood pressure, and red
blood cell production.
In the present study, two novel phenotypic compo-
nents were identified in the HIF2 patients, namely
elevations in basal heart rate and cardiac output, which
Figure 4. Individual responses for HIF2 patients and control participants during the incremental exercise test to exhaustion.
A–C) Venous blood lactate concentration as a function of work rate. D–F) Ventilation as a function of work rate. G–I) PETco2
as a function of work rate. Results are for HIF2 patient 1 (A, D, G), HIF2 patient 2 (B, E, H), and HIF2 patient 3 (C, F, I) and
their associated control participants. Data are minute averages.
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have not been demonstrated in CP. This raises the
possibility that the HIF2 phenotype is not simply a
subset of the CP phenotype. However, a previous study
of the CP phenotype (18) noted trends toward higher
cardiac outputs and heart rates in CP that did not quite
reach statistical significance. As such, it would seem
unlikely that these features are indeed unique to the
HIF2 phenotype.
Other aspects of the CP phenotype appeared to be
either reduced in magnitude or absent in the HIF2
patients. However, a serious limitation of the present
study is the very small number of HIF2 patients that
was available for investigation. Thus, negative find-
ings may simply arise as a type II statistical error
through lack of power, and, therefore, cannot be
used to differentiate HIF2 patients from CP patients.
However, as previous studies of CP patients from our
laboratory have used very similar protocols, and as
some aspects of the CP phenotype are quite extreme,
it is possible that significant differences exist between
the CP and HIF2 patients, despite the very small
numbers in both groups. These comparisons are
made below.
For the ventilatory responses to hypoxia, CP patients
(18) could not be distinguished from HIF2 patients
(CP vs. HIF2: mild hypoxia at 70 Torr, 4.52.3 vs.
0.11.7 L/min, P0.054; moderate hypoxia at 50
Torr, 2111 vs. 108 L/min, P0.29). For the pulmo-
nary vascular responses to hypoxia, CP patients could
be distinguished from HIF2 patients (CP vs. HIF2: mild
hypoxia at 70 Torr, 122 vs. 44 mmHg, P0.053;
moderate hypoxia at 50 Torr, 331 vs. 110 mmHg,
P0.001). Apart from the cardiopulmonary phenotype,
CP patients exhibit an early and above-normal accumu-
lation of lactate in the venous blood during incremen-
tal exercise, and a reduced maximum work rate capac-
ity (19). In that study of CP patients, 3 of 5 patients and
3 of 5 control participants exercised hard enough to
generate a significant metabolic stress, as evidenced by
a venous lactate concentration 	5 mM (47), and this
occurred at 157  12 W for CP patients and 257  12
W for controls (P0.001). Only one HIF2 patient
exercised sufficiently hard to generate a venous
lactate concentration 	5 mM, but this occurred at
270 W—a value that differs significantly (P0.02)
from the distribution of values from the CP patients.
The absence of effect of the HIF-2 mutation on
metabolic function is consistent with studies under-
taken in cell culture, which suggest that HIF-2 plays
no role in regulating the expression of genes that
affect glycolytic function (48). While metabolic ab-
normalities have been observed in HIF-2-null mice,
these changes are only part of a very severe and
extensive overall phenotype associated with complete
HIF-2 inactivation (49).
In summary, the HIF2 phenotype appeared to reca-
pitulate those aspects of the CP phenotype that are
most closely related to the regulation of absolute (or
basal) values for variables within the hematological,
cardiovascular, and respiratory systems. These include
the hematocrit, the (euoxic) pulmonary vascular resis-
tance (as reflected by the pulmonary hypertension),
the ratio of ventilation to metabolic rate (as reflected by
arterial/end-tidal Pco2), the cardiac output, and possi-
bly cardiac sympathetic tone (as reflected by an in-
creased heart rate). Aspects of the CP phenotype that
are not so well replicated by the HIF2 phenotype are
the increased sensitivity of the pulmonary vasculature
to acute hypoxia and the excessive production of lactic
acid during exercise. The limited number of available
patients has made it impossible to draw definitive
conclusions with respect to the ventilatory sensitivity to
hypoxia. While it may be tempting to ascribe those
aspects of the CP phenotype that were not observed in
the HIF2 patients to an elevation of HIF-1, it has been
reported that VHL possesses a number of HIF-indepen-
dent effects (44, 45) and so this is not necessarily
correct.
Hemoglobin concentration, hematocrit, serum iron,
and ferritin were all significantly reduced in one HIF2
patient after venesection. Despite the decrease in blood
viscosity that would have occurred, no associated reduc-
tion in pulmonary arterial systolic pressure was de-
tected. It is possible that the elevated HIF-2 levels in
this patient contributed to maintaining a high pulmo-
nary blood pressure, despite a marked decrease in
hematocrit. However, in a study of venesection in
patients with excessive erythrocytosis from chronic
mountain sickness, pulmonary arterial blood pressure
increased rather than decreased, suggesting that iron
depletion can exacerbate hypoxic pulmonary hyperten-
sion (50). This underlines that the effects of venesec-
tion are not yet clear (51), and an important question
is the extent to which patients with CP or HIF-2 gain
of function erythrocytosis should be venesected.
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